# A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Source: https://onco.cc/trials/nct05456256/  
OnCo record `nct05456256` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Lantern Pharma Inc., now recruiting.

## Summary

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma is a phase 2 interventional study registered as NCT05456256 by Lantern Pharma Inc., with 90 participants planned, started 2023-03-01 and due to reach its primary completion in 2026-12. Interventions recorded: LP-300, Pemetrexed and Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05456256
- Phase: 2
- Setting: Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)
- Sponsor: Lantern Pharma Inc.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT05456256: https://clinicaltrials.gov/study/NCT05456256

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct05456256.json